Proactive Investors - Finance
02 May 2026, 10:30 UTC · 28w ago
Orthocell's Remplir achieves 90% success rate in real-world patient data - ICYMI
Impact · against what's priced in
Orthocell is positioned for a potential valuation rerating as it moves from a domestic proof-of-concept phase to a material revenue inflection point driven by US market expansion. The combination of 90% real-world success rates and established Australian penetration provides a strong foundation for scaling global revenues.
- OCC+0.70
No priced-in read yet





